Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc7.1 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Splicing factor 3 subunit B1 (SF3B1) inhibition in PRL-secreting PitNETs and cross-talk with dopamine receptor type 2 (DRD2)

Di Muro Genesio , Mangili Federica , Barbieri Anna Maria , Esposito Emanuela , Treppiedi Donatella , Arlati Federico , Catalano Rosa , Marra Giusy , Nozza Emma , Arosio Maura , Mantovani Giovanna , Peverelli Erika

Somatic mutations in splicing factor 3 subunit B1 (SF3B1) were found in about 20% of PRL-secreting PitNETs. SF3B1 is involved in pre-mRNA splicing and required for assembly of the U2 complex, which is critical for branch site recognition and the early stages of spliceosome assembly. Patients with mutant prolactinomas showed higher PRL levels and shorter progression-free survival compared to wild-type patients. Aims of the present study were: 1) to characterize the genetic prof...

ea0081rc12.7 | Rapid Communications 12: Reproductive and Developmental Endocrinology | ECE2022

Pubertal induction in girls with hypogonadism: insight into estrogen replacement therapy outcomes and optimization of progesterone introduction

Rodari Giulia , Federici Silvia , Cattoni Alessandro , Todisco Tommaso , Ubertini Graziamaria , Giacchetti Federico , Profka Eriselda , Dall'Antonia Alberta , Cangiano Biagio , Arosio Maura , Bonomi Marco , Cappa Marco , Giavoli Claudia

Background: Pubertal induction in girls with hypogonadism through estrogen replacement therapy (ERT) aims at mimicking physiological puberty. To date, the best induction regimen is still to be established.Aims: By setting up a multicentre clinical registry, we analysed longitudinal data on pubertal induction in girls with hypogonadotropic hypogonadism or premature ovarian insufficiency (congenital, acquired, isolated or associated with multiple pituitary...

ea0081rc13.3 | Rapid Communications 13: Adrenal and Cardiovascular Endocrinology 2 | ECE2022

Steroidomic approach for the characterization of patients with non-alcoholic fatty liver disease

Parasiliti Caprino Mirko , Rosso Chiara , Ponzetto Federico , Paolo Caviglia Gian , Lopez Chiara , Armandi Angelo , Maria Saracco Giorgio , Ghigo Ezio , Bugianesi Elisabetta , Maccario Mauro

Introduction: The onset and progression of liver damage in non-alcoholic fatty liver disease (NAFLD) is tightly associated with metabolic derangements. Steroids may affect lipid metabolism but their alterations in the setting of NAFLD remain to be fully explored.Patients and Methods: We analyzed data from 121 patients with biopsy-proven NAFLD and 108 controls (CT). A panel of 26 steroids (including glucocorticoids, mineralocorticoids, androgens, and prog...

ea0081p549 | Calcium and Bone | ECE2022

Artificial intelligence based on radiomic analysis of lumbar spine computed tomography (ct) scan may improve accuracy in detecting osteoporosis

Biamonte Emilia , Garoli Federico , Levi Riccardo , Vena Walter , Carrone Flaminia , Jafaar Simona , Fornari Maurizio , Grimaldi Marco , Politi Letterio , Lania Andrea , Mazziotti Gherardo

Background: Osteoporosis is characterized by reduced bone mass and a compromised bone microstructure, leading to increased bone fragility and fracture risk. Currently, the gold standard for diagnosis is the bone mineral density (BMD) measurement by DXA. However, approximately half of fragility fractures occurs in the context of normal or slightly decreased BMD values.Protocol: In this cross-sectional study, we performed an artificial intelligence (AI)-ba...

ea0081p179 | Pituitary and Neuroendocrinology | ECE2022

Role of beta arrestins and G proteins in mediating DRD2 signaling in pituitary tumors

Esposito Emanuela , Mangili Federica , Di Muro Genesio , Maria Barbieri Anna , Treppiedi Donatella , arlati federico , Catalano Rosa , Marra Giusy , nozza emma , Arosio Maura , Mantovani Giovanna , Peverelli Erika

Dopamine receptor type 2 (DRD2) agonists (DA) are the first-choice treatment for prolactin (PRL)-secreting pituitary tumors, but poorly effective in non-functioning (NF)-PitNETs. Along with G protein-dependent signaling, DRD2 also mediates non-canonical beta-arrestin-dependent pathways, where reduction of AKT phosphorylation plays a leading role for the antiproliferative effect of DRD2 in pituitary tumors. Through UNC9994 and MLS1547, a beta-arrestin 2-biased and a G protein-b...

ea0081ep49 | Adrenal and Cardiovascular Endocrinology | ECE2022

The different contribution of IGF1R and IR in mediating insulin-like growth factor 2 (IGF2) effects in adrenocortical carcinomas

Catalano Rosa , Nozza Emma , Esposito Emanuela , Barbieri Anna Maria , Marra Giusy , Treppiedi Donatella , Mangili Federica , Di Muro Genesio , Arlati Federico , Morelli Valentina , Arosio Maura , Mantovani Giovanna , Peverelli Erika

Adrenocortical carcinomas (ACCs) are rare endocrine tumors with poor prognosis. They overexpress the insulin-like growth factor 2 (IGF2), that drives a proliferative autocrine loop by binding to IGF1R and IR. The majority of studies focused on IGF1R as mediator of IGF2 biological effects, but recently a high expression of IR, in particular of the isoform A, was observed in most ACCs, suggesting a potential role of this receptor in modulating IGF2 effects in adrenocortical tumo...

ea0090p285 | Adrenal and Cardiovascular Endocrinology | ECE2023

Predictive performance of aldosterone-to-renin ratio in the diagnosis of primary aldosteronism in patients with resistant hypertension

Bioletto Fabio , Lopez Chiara , Bollati Martina , Arata Stefano , Procopio Matteo , Ponzetto Federico , Beccuti Guglielmo , Mengozzi Giulio , Ghigo Ezio , Maccario Mauro , Parasiliti Caprino Mirko

Background: The systematic use of confirmatory tests in the diagnosis of primary aldosteronism (PA) increases costs, risks and complexity to the diagnostic work-up. In light of this, some authors proposed aldosterone-to-renin (ARR) cut-offs and/or integrated flow-charts to avoid this step. Patients with resistant hypertension (RH), however, are characterized by a dysregulated renin-angiotensin-aldosterone system, even in the absence of PA. Thus, it is unclear whether those str...

ea0090p406 | Pituitary and Neuroendocrinology | ECE2023

Somatotroph Pituitary Neuroendocrine Tumors (Pitnets)/Adenomas Expressing Steroidogenic Factor (SF1)

Guaraldi Federica , Roncaroli Federico , Villa Chiara , Zoli Matteo , Waqar Mueez , Higham Claire , Lally Imogen , Baussart Bertrand , Assie Guillaume , Morandi Luca , Mazzatenta Diego , Asioli Sofia

Rationale and aim: A recent pangenomic study documented a subset of somatotroph mostly GNAS-wildtype PitNET/adenomas co-express steroidogenic factor 1 (SF1). Aim of our study was to investigate clinical and molecular features of a cohort of these tumour subtype. Study sample: We identified 20 cases of SF1-expressing somatotropinomas out of 173 (11.6%) operated via transsphenoidal endoscopic approach in 3 referral Pituitary Centers patients. Pre- and post...

ea0065op6.2 | Neuroendocrinology, Pituitary and Neoplasia | SFEBES2019

Transcriptomic analyses reveal deregulation of focal adhesion pathway in Aip KO mice and AIP mutation positive human tumours

Bollington Mark , Mistry Anisha , Solomou Antonia , Barry Sayka , Begalli Federica , Vignola Maria , Lim Chung Thong , Herincs Maria , Roncaroli Federico , Gaston-Massuet Carles , Korbonits Marta

Introduction: AIP mutations are responsible for 15-30% of cases of familial isolated pituitary adenomas. The pathophysiology that drives this AIP-related pituitary tumorigenesis is not fully understood. We developed a pituitary-specific Aip knockout (KO) mouse model, which mostly recapitulates the human phenotype.Aims: To performed comparative gene expression analysis of Aip-KO mouse pituitary tumours and AIP mutation positive ...

ea0067o46 | Oral Presentations | EYES2019

Effect of treatment with Cinacalcet on TBS and BMD in patients with chronic renal failure with secondary hyperparathyroidism in hemodialysis

Reyes Laura Mola , Maria Soledad Librizzi , Martinez Eduardo Hernandez , Herrero Eva Merida , Cuellar Hernando Trujillo , Arriscado Cristina Martin , Carranza Federico Hawkins

Background: Fractures are frequent in patients with chronic renal failure (CRF) with secondary hyperparathyroidism (SHPT) undergoing hemodialysis. Cinacalcet (CT) is a drug used in the reduction of hypercalcemia in these patients that acts through the lintel calcium sensor in the parathyroid gland. Recently, it has been pointed out that CT can reduce fractures in these patients by unknown mechanisms (EVOLVE Trials 2015).Objectives: To evaluate the effect...